Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Anti-CD20 monoclonal antibody - Immunomedics; hA20; Humanised anti-CD20 monoclonal antibody; IMMU-106; Monoclonal antibody hA20; Monoclonal antibody IMMU-106; Veltucyn

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Developer Immunomedics; Weill Cornell Medical College
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura; Pemphigus; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Idiopathic thrombocytopenic purpura; Non-Hodgkin's lymphoma
  • Phase I/II Follicular lymphoma
  • No development reported Chronic lymphocytic leukaemia
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Apr 2017 Immunomedics terminates a phase I/II trial due to slow patient accrual in Follicular lymphoma (Combination therapy, First-line therapy) in USA (IV) (NCT01147393)
  • 03 Jun 2016 Phase-II clinical trials in Idiopathic thrombocytopenic purpura in USA (SC) (Immunomedics pipeline, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top